https://scholars.lib.ntu.edu.tw/handle/123456789/633231
標題: | Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study | 作者: | Yang, Chin-Yi Lai, Po-Ju Chen, Chun-Bing Chan, Tom C Hui, Rosaline Chung-Yee Huang, Yu-Huei Tseng, Han-Chi Lin, Shang-Hung Lu, Chun-Wei Lee, Hua-En Lin, Jing-Yi Chi, Min-Hui Tsai, Ming-Feng Hwang, Yih-Shiou Wang, Chuang-Wei CHIA-YU CHU Chung, Wen-Hung |
關鍵字: | atopic dermatitis; biomarker; dupilumab; eczema phenotype; efficacy | 公開日期: | 21-十月-2022 | 卷: | 11 | 期: | 20 | 來源出版物: | Journal of clinical medicine | 摘要: | To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18-87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator's Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633231 | ISSN: | 2077-0383 | DOI: | 10.3390/jcm11206209 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。